Circulating tumor DNA in primary mediastinal large B-cell lymphoma versus classical Hodgkin lymphoma: a retrospective study

References

• Kurtz DM, Scherer F, Jin MC, et al. Circulating tumor DNA measurements as early outcome predictors in diffuse large B-Cell lymphoma. J Clin Oncol. 2018;36(28):2845–2853.
   PubMed Web of Science ®Google Scholar
• Spina V, Bruscaggin A, Cuccaro A, et al. Circulating tumor DNA reveals genetics, clonal evolution, and residual disease in classical Hodgkin lymphoma. Blood. 2018;131(22):2413–2425.
   PubMed Web of Science ®Google Scholar
• Camus V, Viennot M, Lequesne J, et al. Targeted genotyping of circulating tumor DNA for classical Hodgkin lymphoma monitoring: a prospective study. Haematologica. 2021;106(1):154–162.
   PubMed Web of Science ®Google Scholar
• Desch A-K, Hartung K, Botzen A, et al. Genotyping circulating tumor DNA of pediatric Hodgkin lymphoma. Leukemia. 2020;34(1):151–166.
   PubMed Web of Science ®Google Scholar
• Lazarovici J, Terroir M, Arfi-Rouche J, et al. Poor predictive value of positive interim FDG-PET/CT in primary mediastinal large B-cell lymphoma. Eur J Nucl Med Mol Imaging. 2017;44(12):2018–2024.
   PubMed Web of Science ®Google Scholar
• Martelli M, Ceriani L, Zucca E, et al. [18F]fluorodeoxyglucose positron emission tomography predicts survival after chemoimmunotherapy for primary mediastinal large B-Cell lymphoma: Results of the international extranodal lymphoma study group IELSG-26 study. J Clin Oncol. 2014;32(17):1769–1775.
   PubMed Web of Science ®Google Scholar
• Tiacci E, Ladewig E, Schiavoni G, et al. Pervasive mutations of JAK-STAT pathway genes in classical Hodgkin lymphoma. Blood. 2018;131(22):2454–2465.
   PubMed Web of Science ®Google Scholar
• Wienand K, Chapuy B, Stewart C, et al. Genomic analyses of flow-sorted Hodgkin Reed-Sternberg cells reveal complementary mechanisms of immune evasion. Blood Adv. 2019;3(23):4065–4080.
   PubMed Web of Science ®Google Scholar
• Lennerz JK, Hoffmann K, Bubolz A-M, et al. Suppressor of cytokine signaling 1 gene mutation status as a prognostic biomarker in classical Hodgkin lymphoma. Oncotarget. 2015;6(30):29097–29110.
   PubMedGoogle Scholar
• Reichel J, Chadburn A, Rubinstein PG, et al. Flow sorting and exome sequencing reveal the oncogenome of primary Hodgkin and Reed-Sternberg cells. Blood. 2015;125(7):1061–1072.
   PubMed Web of Science ®Google Scholar
• Jardin F, Pujals A, Pelletier L, et al. Recurrent mutations of the exportin 1 gene (XPO1) and their impact on selective inhibitor of nuclear export compounds sensitivity in primary mediastinal B-cell lymphoma: XPO1 mutations in primary mediastinal B-Cell lymphoma. Am J Hematol. 2016;91(9):923–930.
   PubMed Web of Science ®Google Scholar
• Dubois S, Viailly P-J, Mareschal S, et al. Next-Generation sequencing in diffuse large B-Cell lymphoma highlights molecular divergence and therapeutic opportunities: a LYSA study. Clin Cancer Res. 2016;22(12):2919–2928.
   PubMed Web of Science ®Google Scholar
• Melzner I, Bucur AJ, Brüderlein S, et al. Biallelic mutation of SOCS-1 impairs JAK2 degradation and sustains phospho-JAK2 action in the MedB-1 mediastinal lymphoma line. Blood. 2005;105(6):2535–2542.
   PubMed Web of Science ®Google Scholar
• Ritz O, Guiter C, Castellano F, et al. Recurrent mutations of the STAT6 DNA binding domain in primary mediastinal B-cell lymphoma. Blood. 2009;114(6):1236–1242.
   PubMed Web of Science ®Google Scholar
• Mottok A, Hung SS, Chavez EA, et al. Integrative genomic analysis identifies key pathogenic mechanisms in primary mediastinal large B-cell lymphoma. Blood. 2019;134(10):802–813.
   PubMed Web of Science ®Google Scholar
• Mansouri L, Noerenberg D, Young E, et al. Frequent NFKBIE deletions are associated with poor outcome in primary mediastinal B-cell lymphoma. Blood. 2016;128(23):2666–2670.
   PubMed Web of Science ®Google Scholar
• Bohers E, Viailly P-J, Becker S, et al. Non-invasive monitoring of diffuse large B-cell lymphoma by cell-free DNA high-throughput targeted sequencing: analysis of a prospective cohort. Blood Cancer J. 2018;8(8):74.
   PubMedGoogle Scholar
• Fontanilles M, Marguet F, Bohers É, et al. Non-invasive detection of somatic mutations using next-generation sequencing in primary Central nervous system lymphoma. Oncotarget. 2017;8(29):48157–48168.
   PubMed Web of Science ®Google Scholar
• Laurent C, Baron M, Amara N, et al. Impact of expert pathologic review of lymphoma diagnosis: Study of patients from the french lymphopath network. J Clin Oncol. 2017;35(18):2008–2017.
   PubMed Web of Science ®Google Scholar
• Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the world health organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375–2390.
   PubMed Web of Science ®Google Scholar
• Meignan M, Sasanelli M, Casasnovas RO, et al. Metabolic tumour volumes measured at staging in lymphoma: methodological evaluation on phantom experiments and patients. Eur J Nucl Med Mol Imaging. 2014;41(6):1113–1122.
   PubMed Web of Science ®Google Scholar
• Stroun M, Lyautey J, Lederrey C, et al. About the possible origin and mechanism of circulating DNA apoptosis and active DNA release. Clin Chim Acta Int J Clin Chem. 2001;313(1-2):139–142.
   PubMed Web of Science ®Google Scholar
• Jahr S, Hentze H, Englisch S, et al. DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res. 2001;61(4):1659–1665.
   PubMed Web of Science ®Google Scholar
• Scherer F, Kurtz DM, Newman AM, et al. Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA. Sci Transl Med. 2016;8(364):364ra155.
   PubMed Web of Science ®Google Scholar
• Sherry ST, Ward MH, Kholodov M, et al. dbSNP: the NCBI database of genetic variation. Nucleic Acids Res. 2001;29(1):308–311.
   PubMed Web of Science ®Google Scholar
• O'Leary NA, Wright MW, Brister JR, et al. Reference sequence (RefSeq) database at NCBI: current status, taxonomic expansion, and functional annotation. Nucleic Acids Res. 2016;44(D1):D733–D745.
   PubMed Web of Science ®Google Scholar
• Landrum MJ, Lee JM, Benson M, et al. ClinVar: improving access to variant interpretations and supporting evidence. Nucleic Acids Res. 2018;46(D1):D1062–D1067.
   PubMed Web of Science ®Google Scholar
• dbNSFP: a lightweight database of human nonsynonymous SNPs and their functional predictions - PubMed. [cited 2021 June 29]. Available from: https://pubmed.ncbi.nlm.nih.gov/21520341/
   Google Scholar
• Li Q, Wang K. InterVar: Clinical interpretation of genetic variants by the 2015 ACMG-AMP guidelines. Am J Hum Genet. 2017;100(2):267–280.
   PubMed Web of Science ®Google Scholar
• , Auton A, Brooks LD, Durbin RM, et al. A global reference for human genetic variation. Nature. 2015;526(7571):68–74.
   PubMed Web of Science ®Google Scholar
• Tate JG, Bamford S, Jubb HC, et al. COSMIC: the catalogue of somatic mutations in cancer. Nucleic Acids Res. 2019;47(D1):D941–D947.
   PubMed Web of Science ®Google Scholar
• Récher C, Coiffier B, Haioun C, et al. Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial. Lancet. 2011;378(9806):1858–1867.
   PubMed Web of Science ®Google Scholar
• Delfau-Larue M-H, van der Gucht A, Dupuis J, et al. Total metabolic tumor volume, circulating tumor cells, cell-free DNA: distinct prognostic value in follicular lymphoma. Blood Adv. 2018;2(7):807–816.
   PubMed Web of Science ®Google Scholar
• Lakhotia R, Melani C, Pittaluga S, et al. Circulating tumor DNA dynamics during therapy predict outcomes in mantle cell lymphoma. Blood. 2018;132(Supplement 1):147–147.
   Google Scholar
• Macaulay C, Alig S, Kurtz DM, et al. Interim circulating tumor DNA as a prognostic biomarker in the setting of interim PET-Based adaptive therapy for DLBCL. Blood. 2019;134(Supplement_1):1600–1600.
   Google Scholar
• Pang D, Jiang X, Huang L, et al. Ctdna monitoring in predicting relapse of primary mediastinal B-Cell lymphoma. Blood. 2020;136(Supplement 1):36–36.
   PubMedGoogle Scholar
• Chapuy B, Stewart C, Dunford AJ, et al. Genomic analyses of PMBL reveal new drivers and mechanisms of sensitivity to PD-1 blockade. Blood. 2019;134(26):2369–2382.
   PubMed Web of Science ®Google Scholar
• Schmitz R, Stanelle J, Hansmann M-L, et al. Pathogenesis of classical and Lymphocyte-Predominant Hodgkin lymphoma. Annu Rev Pathol. 2009;4(1):151–174.
   PubMedGoogle Scholar
• Pittaluga S, Nicolae A, Wright GW, et al. Gene expression profiling of mediastinal gray zone lymphoma and its relationship to primary mediastinal B-cell lymphoma and classical Hodgkin lymphoma. Blood Cancer Discov. 2020;1(2):155–161.
   PubMedGoogle Scholar
• Dubois S, Ruminy P, Bohers E, et al. Concomitant occurrence of genetically distinct Hodgkin lymphoma and primary mediastinal lymphoma. Case Rep 2021;9(8):e04504.
   Google Scholar
• Schmitz R, Hansmann M-L, Bohle V, et al. TNFAIP3 (A20) is a tumor suppressor gene in Hodgkin lymphoma and primary mediastinal B cell lymphoma. J Exp Med. 2009;206(5):981–989.
   PubMed Web of Science ®Google Scholar
• Steidl C, Gascoyne RD. The molecular pathogenesis of primary mediastinal large B-cell lymphoma. Blood. 2011;118(10):2659–2669.
   PubMed Web of Science ®Google Scholar
• Sarkozy C, Hung SS, Chavez EA, et al. Mutational landscape of gray zone lymphoma. Blood. 2021;137(13):1765–1776.
   PubMed Web of Science ®Google Scholar
• Beyaert R, Heyninck K, Van Huffel S. A20 and A20-binding proteins as cellular inhibitors of nuclear factor-kappa B-dependent gene expression and apoptosis. Biochem Pharmacol. 2000;60(8):1143–1151.
   PubMed Web of Science ®Google Scholar
• Healy JA, Nugent A, Rempel RE, et al. GNA13 loss in germinal center B cells leads to impaired apoptosis and promotes lymphoma in vivo. Blood. 2016;127(22):2723–2731.
   PubMed Web of Science ®Google Scholar
• Popov SW, Moldenhauer G, Wotschke B, et al. Target sequence accessibility limits Activation-Induced cytidine deaminase activity in primary mediastinal B-Cell lymphoma. Cancer Res. 2007;67(14):6555–6564.
   PubMed Web of Science ®Google Scholar
• Greiner A, Tobollik S, Buettner M, et al. Differential expression of activation-induced cytidine deaminase (AID) in nodular lymphocyte-predominant and classical Hodgkin lymphoma. J Pathol. 2005;205(5):541–547.
   PubMed Web of Science ®Google Scholar
• Bessi L, Viailly P-J, Bohers E, et al. Somatic mutations of cell-free circulating DNA detected by targeted next-generation sequencing and digital droplet PCR in classical Hodgkin lymphoma. Leuk Lymphoma. 2019;60(2):498–502.
   PubMed Web of Science ®Google Scholar
• Ferrone CK, Blydt-Hansen M, Rauh MJ. Age-Associated TET2 mutations: Common drivers of myeloid dysfunction, cancer and cardiovascular disease. IJMS. 2020;21(2):626.
   Google Scholar
• Buscarlet M, Provost S, Zada YF, et al. DNMT3A and TET2 dominate clonal hematopoiesis and demonstrate benign phenotypes and different genetic predispositions. Blood. 2017;130(6):753–762.
   PubMed Web of Science ®Google Scholar
• Batalini F, Peacock EG, Stobie L, et al. Li-Fraumeni syndrome: not a straightforward diagnosis anymore-the interpretation of pathogenic variants of low allele frequency and the differences between germline PVs, mosaicism, and clonal hematopoiesis. Breast Cancer Res. 2019;21(1):107.
   PubMed Web of Science ®Google Scholar
• Jaiswal S, Ebert BL. Clonal hematopoiesis in human aging and disease. Science. 2019;366(6465):eaan4673.
   PubMed Web of Science ®Google Scholar
• Viganò E, Gunawardana J, Mottok A, et al. Somatic IL4R mutations in primary mediastinal large B-cell lymphoma lead to constitutive JAK-STAT signaling activation. Blood. 2018;131(18):2036–2046.
   PubMed Web of Science ®Google Scholar
• Twa DDW, Chan FC, Ben-Neriah S, et al. Genomic rearrangements involving programmed death ligands are recurrent in primary mediastinal large B-cell lymphoma. Blood. 2014;123(13):2062–2065.
   PubMed Web of Science ®Google Scholar
• Lei KIK, Chan LYS, Chan WY, et al. Quantitative analysis of circulating cell-free Epstein-Barr virus (EBV) DNA levels in patients with EBV-associated lymphoid malignancies. Br J Haematol. 2000;111(1):239–246.
   PubMed Web of Science ®Google Scholar
• Christensen E, Birkenkamp-Demtröder K, Sethi H, et al. Early detection of metastatic relapse and monitoring of therapeutic efficacy by ultra-deep sequencing of plasma cell-free DNA in patients with urothelial bladder carcinoma. J Clin Oncol. 2019;37(18):1547–1557.
   PubMed Web of Science ®Google Scholar
• Elshimali Y, Khaddour H, Sarkissyan M, et al. The clinical utilization of circulating cell free DNA (CCFDNA) in blood of cancer patients. Int J Mol Sci. 2013;14(9):18925–18958.
   PubMed Web of Science ®Google Scholar
• Kurtz DM, Chabon JJ, Soo J, et al. Phased variants improve DLBCL minimal residual disease detection at the end of therapy. J Clin Oncol. 2021;39(15_suppl):7565–7565.
   Web of Science ®Google Scholar
• Mottok A, Wright G, Rosenwald A, et al. Molecular classification of primary mediastinal large B-cell lymphoma using routinely available tissue specimens. Blood. 2018;132(22):2401–2405.
   PubMed Web of Science ®Google Scholar